Core Viewpoint - The financial performance of the company shows a significant slowdown in growth compared to the previous year, raising concerns about its future prospects [1] Financial Performance - The company reported a revenue of 31.13 billion and a net profit of 11.82 billion for the first half of the year [1] - Revenue growth has decreased to 22.5% and net profit growth to 20.2%, compared to last year's growth rates of 58% and 47% respectively [1] Controversy and Market Impact - Since May, the company has faced scrutiny over the "recombinant collagen content" issue, which led to a market value loss exceeding 300 billion [1] - The company acknowledged the limitations of its testing methods in response to the controversy [1] Industry Positioning - Following the controversy, the company has positioned itself as a "rule-maker" in the industry by participating in the drafting of the new pharmaceutical industry standard for "recombinant collagen dressings" [1] - This raises questions about the potential conflict of interest when a participant in the industry also sets the rules [1]
利润增速踩刹车，争议漩涡中巨子生物转身成为“标准制定者”？